Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 mai 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
Kallelse till extra bolagsstämma i Infant Bacterial Therapeutics
16 mai 2023 17h31 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till extra bolagsstämma fredagen den 9 juni 2023 kl. 10.00 i bolagets lokaler på Bryggargatan 10, Stockholm. ...
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
16 mai 2023 17h31 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00...
IBT beslutar om en företrädesemisson
16 mai 2023 17h00 HE
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT resolves on a rights issue
16 mai 2023 17h00 HE
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Årsstämma i Infant Bacterial Therapeutics
08 mai 2023 11h25 HE
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 8 maj 2023 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Annual General Meeting of Infant Bacterial Therapeutics
08 mai 2023 11h25 HE
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 31 mars 2023
08 mai 2023 07h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de senaste månaderna har det skett betydelsefulla framsteg inom utvecklingen av mikrobiom-läkemedel. Ferrings/Rebiotics produkt REBYOTA™ godkändes av FDA i slutet av förra året...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
08 mai 2023 07h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics' product REBYOTA™ was approved by the...
Kallelse till årsstämma i Infant Bacterial Therapeutics
03 avr. 2023 05h20 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till årsstämma den 8 maj 2023 kl. 15.00 på Westmanska Palatset, konferensrum Bryggarkungen, Holländargatan 17,...